However, there is an advanced pipeline of vaccine research currently in clinical and preclinical studies including live-attenuated vaccine candidates as well as virus-vectored and virus-like particle-based vaccines.doi:10.1080/14760584.2020.1775076Usa Thisyakorn...
CMAA serves on the Independent Data and Monitoring Committee for ongoing dengue vaccine trials being conducted by Sanofi-Pasteur. Author information Authors and Affiliations Center for Infectious Diseases Research, Instituto Nacional de Salud Pública, Av. Universidad 655. Santa María Ahuacatitlán, Cuern...
The data presented in this article indicate that immunization with NS1 could provide crucial protection against severe dengue disease and argue for the inclusion in dengue vaccine. Article CAS PubMed Google Scholar Modhiran, N. et al. Dengue virus NS1 protein activates cells via Toll-like ...
To date, the efficacy of dengue vaccine has been accessed in eleven countries with immune response of 59% of vaccinated people39, suggesting that high quality studies are needed to have highly effective vaccine and antiretroviral treatment to rapidly curb the burden of dengue fever in Africa. ...
Efforts to develop effectivedengue vaccineshave been under way for many years, but field trials have been hindered by the concern that a partially protective vaccine might elicit only nonneutralizing antibodies, rendering subjects susceptible to hemorrhagic fever on subsequent exposure to a natural infect...
Interpretation The OnSite IgG RDT should provide a valuable tool for screening for previous dengue infection at the point of vaccination. In individuals who were OnSite IgG RDT-positive, the vaccine efficacy of CYD-TDV was high across all three age groups. Funding Sanofi Pasteur.Previous...
vaccine for dengue infection is in progress. Until 2007, Zika virus [also transmitted byAedesspecies] was associated with only sporadic mild infections in Africa and Asia. In 2007, Zika virus for the first time caused an outbreak beyond Africa and Asia to the Yap Island in the Federated ...
REVIEWS Prospects for a dengue virus vaccine Stephen S. Whitehead*, Joseph E. Blaney*, Anna P. Durbin‡ and Brian R. Murphy* Abstract | The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical ...
000 deaths per year4. A major hurdle in developing a safe vaccine for Dengue has been the presence of four circulating serotypes (DENV1-4) against which sufficient cross-protection must be conferred: incomplete protection against any of the four serotypes can lead to exacerbation of the ...
and these mutants are tested in an animal model system (e.g., in a mouse and/or a monkey model system) to determine whether the resulting mutants are attenuated. Mutants that are found to be attenuated can then be used as new vaccine strains that have increased safety, due to attenuation...